Companies › Toray Industries
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRK-950 | – | Phase 2 | Gastric Adenocarcinoma; Solid Tumor | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03872947 | TRK-950 | Phase 1 | Solid Tumor | Oncology | Jul 2026 |
| NCT06038578 | TRK-950 | Phase 2 | Gastric Adenocarcinoma | Oncology | Oct 2027 |
| NCT05423262 | TRK-950 | Phase 1 | Solid Tumor | Oncology | Mar 2028 |
No annotated target.
–
iOnctura SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax Klus Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.